SCHEMBL3823738

SCHEMBL3823738

[CH2]N1C=CCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10321131 0.63
SCHEMBL10751979 0.62
SCHEMBL3602471 0.62
SCHEMBL9572743 0.59
SCHEMBL3675215 0.57
SCHEMBL10373037 0.57
SCHEMBL3853469 0.57
SCHEMBL7104332 0.47
SCHEMBL2554291 0.44
SCHEMBL6517038 0.42

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091929-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS The European Molecular Biology Laboratory (DE) 2009-08-26 EP claimed
CN-101421257-A Agents that disrupt cellular replication and their use in inhibiting pathological conditions EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) 2009-04-29 CN claimed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO claimed
US-20020082253-A1 Novel isoxazoline fibrinogen receptor antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-06-27 US claimed
EP-0569333-B1 Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids NOVARTIS AG (CH) 1999-01-07 EP claimed
US-5424441-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1995-06-13 US claimed
EP-0569333-A2 Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids CIBA-GEIGY AG (CH) 1993-11-10 EP claimed
EP-3131897-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2022-06-15 EP disclosed
EP-3131896-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2019-01-30 EP disclosed
US-9969724-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-9808445-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-07 US disclosed
US-20170129880-A1 FACTOR IXa INHIBITORS MERCK SHARP & DOHME LLC 2017-05-11 US disclosed
EP-3131896-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-02-22 EP disclosed
WO-2007113005-A2 2-SUBSTITUTED 3-AMINOSULFONYL-THIOPHENE DERIVATIVES AS AURORA KINASE INHIBITORS EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) 2007-10-11 WO disclosed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO disclosed
EP-0569333-B1 Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids NOVARTIS AG (CH) 1999-01-07 EP disclosed
US-5424441-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1995-06-13 US disclosed
US-5332729-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1994-07-26 US disclosed
EP-0569333-A2 Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids CIBA-GEIGY AG (CH) 1993-11-10 EP disclosed
EP-0562832-A1 Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use SANKYO COMPANY LIMITED (JP) 1993-09-29 EP disclosed